AR Asset Management Inc. Makes New $583,000 Investment in Novo Nordisk A/S $NVO

AR Asset Management Inc. purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,862 shares of the company’s stock, valued at approximately $583,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. Boston Partners purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth about $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares during the last quarter. Bank of Montreal Can lifted its position in Novo Nordisk A/S by 138.9% during the 4th quarter. Bank of Montreal Can now owns 2,525,827 shares of the company’s stock worth $128,514,000 after acquiring an additional 1,468,409 shares during the period. Finally, Quadrature Capital Ltd purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $59,882,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.4%

Shares of NYSE NVO opened at $48.22 on Thursday. The firm has a market cap of $215.29 billion, a price-to-earnings ratio of 11.32, a price-to-earnings-growth ratio of 4.50 and a beta of 0.77. The company’s 50-day simple moving average is $46.23 and its 200-day simple moving average is $45.75. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities analysts predict that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Negative Sentiment: Novo Nordisk sued Eli Lilly, accusing the rival of false and misleading advertising for Zepbound and Mounjaro, saying the campaigns rely on outdated clinical data and unfairly compare Lilly’s drugs against Novo’s products. Reuters article
• Neutral Sentiment: Several outlets highlighted the lawsuit as a major escalation in the obesity-drug rivalry, but the immediate market reaction suggests investors are still weighing whether the legal move will protect Novo’s market share or simply underscore stronger competition from Lilly. CNBC article
• Positive Sentiment: Novo Nordisk also expanded its DKK 15 billion share repurchase program, a capital-return move that can support investor sentiment and signal management confidence in the company’s valuation. TipRanks article

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NVO shares. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Finally, Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.